programme for outpatient and medical records was consulted. Data collected for each patient were: sex, age, menopause status, performance status (PS), cancer stage, presence of visceral metastatic disease, therapeutic scheme and number of cycles received. The safety profile was assessed from the number of adverse events (AE), and the severity of AEs was graded on the basis of the common terminology criteria for adverse events, V.5.0. Number of patients and reasons for delays and dose reductions were also determined. Results 34 patients, 100% women, were included, with an average age of 60 (47-81) years, of whom 71% were postmenopausal. 29 patients presented at the beginning of treatment with PS £1. The percentage of patients with metastatic disease was 100%, of whom 76% had visceral metastases. The schemes, average numbers and range of cycles were: palbociclib 125 mg every 3 weeks, 7 (1-17) cycles. 105 AE occurred in 31 patients (91%): 54 haematological, 23 metabolic, 10 digestive, 7 asthenia, 2 cases of infections and 9 other causes. The degree of severity was: anaemia, anorexia asthenia, diarrhoea, dysgeusia, increased levels of GGT/AST/ALT/LDH, mucositis, nausea, neutropenia, itching, palmar-plantar erythrodysaesthesia syndrome, thrombopenia, urticaria and vomiting, grade 1 (59%); anaemia, anorexia, asthenia, headaches, GGT increased, infections, mucositis, nausea, neutropenia and vomiting, grade 2 (30%); and asthenia, neutropenia and GGT increased, grade 3 (12%). There were 13 patients who delayed treatment, and neutropenia was the reason in 85% of patients. 6% of patients had reduced doses of palbociclib because of neutropenia or mucositis. Conclusion and relevance There was a high incidence of AE, the most frequent being grade 1. The most common AE were haematological, with neutropenia being the highest degree. Our studies suggested a high percentage of delays and dose reductions.

No abstract

contraindicated medications include: unadministered contraindicated medications (220 cases, 42.8%); drugs taken intermittently or pro re nata (PRN) (147, 28.6%); administered by a clinical decision (79, 15.4%); local administration (21, 4.1%); meaningless words(44, 8.6%); and emergency medication (three, 0.6%). The reasons for prescribing contraindicated medications with drug-drug interaction in cases of anti-diabetic agents with CT contrast medium were as follows: unadministered contraindicated medications(95 cases, 76.0%), meaningless words (22, 17.6%) and administered by a clinical decision (eight, 6.4%). Reasons for other genitourinary organ and rectal agents with vasodilator were PRN (54 cases, 38.3%), administered by a clinical decision (42, 29.8%), unadministered contraindicated medications (29, 20.6%) and meaningless words (16, 11.3%). Reasons for NSAID with other cardiovascular drugs were PRN (65 cases, 69.9%), unadministered contraindicated medications (16, 17.2%) and local administration (13, 28.9%). Conclusion We confirmed that certain medications were sometimes prescribed using an incorrect reason. Some clinicians input a reason that was something other than a PRN drug use, or entered a meaningless words. It is necessary to improve the system of entering the reasons why clinicians prescribe contraindicated drugs. REFERENCES AND/OR ACKNOWLEDGEMENTSWe acknowledge the assistance of Soojeong Yoon.No conflict of interest.

No abstract

Bacteria causing chronic infection was P aeruginosa in BC (n=7;100%), and in LT, P aeruginosa (n=6; 75%) and Proteus mirabilis (n=2; 25%). AZLI treatment duration was 20.6±14.2 months (BC) and 10.1±9.7 months (LT). Respiratory function tests during AZLI (mean values of the population) are shown in table 1. Comparing BC with LT, a statistically significant improvement was observed in FVC (p=0.011) and FEF25-75 (p=0.005) but this was not clinically relevant. BC annual emergency admissions were 0.07 before and 0.42 during AZLI; annual rates of hospital admissions were 0.44 and 0.55, respectively. Remission data (negative results in sputum burdens) were: BC (n=2, 28.6%) and LT (n=1, 12.5%). The most commonly reported treatment emergent adverse effects (AE) were dyspnoea, bronchospasm and arthralgias in BC (n=3; 42,9%). There were no AE in LT and no deaths in either group. Conclusion and relevance The results suggest that off-label use of AZLI in complicated chronic infected patients could control gram negative infection and neutralise sputum burdens in some cases, while maintaining lung function and decreasing accelerated clinical deterioration. REFERENCES AND/OR ACKNOWLEDGEMENTS No conflict of interest.